Start Your Free Review
Answer 2-3 quick questions to review your potential case.
Verified against court records, regulatory records, and peer-reviewed research.
How Hair Relaxers Cause Uterine Cancer
Chemical hair relaxers contain endocrine-disrupting chemicals that mimic estrogen when absorbed through the scalp. Chronic estrogen overstimulation drives abnormal cell growth in the uterine endometrium — the mechanism underlying most endometrial cancers. The Sister Study's hazard ratio of 2.55 means frequent relaxer users face more than double the uterine cancer risk of non-users.
Uterine Cancer Survival and Treatment
When caught early (Stage I), uterine cancer has a 5-year survival rate of about 95%. But advanced-stage disease has much worse outcomes. Treatment typically involves hysterectomy (removal of the uterus), often with bilateral salpingo-oophorectomy (removal of ovaries), radiation, and possibly chemotherapy. For younger women, this means permanent loss of fertility.
The Racial Disparity
Black women die of uterine cancer at twice the rate of white women — one of the largest racial disparities in cancer mortality. This disparity has been attributed to later diagnosis, more aggressive tumor subtypes, and barriers to care. The hair relaxer litigation adds another factor: disproportionate exposure to EDC-containing products specifically marketed to Black women.
Building Your Uterine Cancer Claim
Key evidence: medical records documenting uterine cancer diagnosis and treatment, history of regular hair relaxer use (product names, frequency, duration), pathology reports (tumor type and stage), and timeline showing cancer diagnosis followed prolonged relaxer use.
Scientific Evidence
Hair Relaxer Use and Risk of Uterine Cancer in the Black Women's Health Study
Bertrand KA, Coogan PF, Palmer JR (2023). Environmental Research
View on PubMed→Use of Straighteners and Other Hair Products and Incident Uterine Cancer
Chang CJ, O'Brien KM, Keil AP, Gaston SA, Jackson CL, Sandler DP, White AJ (2022). Journal of the National Cancer Institute
View on PubMed→Use of Hair Products in Relation to Ovarian Cancer Risk
White AJ, Sandler DP, et al. (2021). Carcinogenesis
View on PubMed→Frequently Asked Questions
What is the hair relaxer litigation about?
Do I qualify for a hair relaxer lawsuit?
Is there a deadline to file a hair relaxer claim?
How much does it cost to pursue a hair relaxer claim?
What kinds of compensation can a hair relaxer claim seek?
Related Pages
Hair Relaxer Ovarian Cancer
The Sister Study found hair relaxer users face a 2.19x increased risk of ovarian cancer. Ovarian cancer is often called the "silent killer" because symptoms are vague until advanced stages, making early detection difficult.
Hair Relaxer Endometriosis
Chemical hair relaxers contain EDCs linked to endometriosis — a painful condition where uterine-like tissue grows outside the uterus. Phthalates and parabens in relaxers promote endometrial implant growth through estrogen mimicry.
Hair Relaxer Settlement Amounts
No hair relaxer cases have settled or gone to trial yet. Attorney estimates project $90,000–$1,000,000+ depending on injury type and severity. Bellwether trials expected in 2027 will establish actual case values.
L'Oréal Hair Relaxer Lawsuit
L'Oréal is the primary defendant in the hair relaxer MDL through its subsidiary SoftSheen-Carson, maker of Dark & Lovely and Optimum Care. L'Oréal is the world's largest beauty company with €38+ billion in annual revenue.
Revlon Dark and Lovely Lawsuit
Revlon is a defendant in the hair relaxer MDL despite filing bankruptcy in 2022. Revlon maintains insurance coverage and allocated ~$44 million for hair relaxer claims in its reorganization plan. Products include Creme of Nature and Revlon Realistic.
Hair Relaxer Chemical Exposure
Hair relaxers contain at least 45 endocrine-disrupting chemicals across 10 chemical classes. 84% of these chemicals are NOT listed on product labels. The chemicals enter the body through the scalp, whose protective barrier is compromised by the relaxing process itself.
Hair Relaxer Lawsuit Black Women
Hair relaxer lawsuits disproportionately affect Black women, who were the primary marketing target, comprise 60% of affected users, and face twice the uterine cancer mortality rate of white women. This is both a product liability and a racial justice case.
Hair Relaxer Cancer Lawsuits Lawsuit
Chemical hair relaxers and straighteners contain endocrine-disrupting chemicals (EDCs) — including phthalates, parabens, formaldehyde, and cyclosiloxanes — that mimic estrogen and disrupt the hormonal system. The NIH/NIEHS Sister Study (2022) found that women who frequently used these products faced more than double the risk of uterine cancer. Over 14,700 lawsuits are consolidated in MDL 3060 in the Northern District of Illinois, with bellwether trials expected in 2027. The litigation disproportionately affects Black women, who were the primary marketing target and comprise approximately 60% of affected users.
View full case overview